Background: Meta-analyses enable summarization and interpretation of data across clinical
trials. When applied to safety data they allow for detection of rare events. Recently, a 13 …

The thirteen valent pneumococcal conjugate vaccine (PCV13, Prevenar 13Ô) is the broader
coverage successor to the highly effective seven valent vaccine (PCV7, PrevenarÔ) which …

Background: The global distribution of pneumococcal disease and emergence of
nonvaccine pneumococcal serotypes prompted the development of a 13-valent …

This was a randomized safety/immunogenicity evaluation of PCV7 primary series at 3, 4, 5
months in healthy Chinese infants. Eight hundred subjects were randomized to Group 1 …

Background: Pneumococcal disease remains a public health priority worldwide. This phase
2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and …

Introduction The invasive pneumococcal diseases (IPDs) caused by Streptococcus
pneumoniae pose an enormous threat to children under 5 years of age. However, routine …

Introduction: The inclusion of the heptavalent pneumococcal conjugate vaccine (PCV7) in
the immunization schedule of infants and young children has greatly reduced the incidence …

Importance Immunization schedules with pneumococcal conjugate vaccine (PCV) differ
among countries regarding the number of doses, age at vaccinations, and interval between …

BACKGROUND: As 13-valent pneumococcal conjugate vaccine (PCV13) is introduced,
children who began vaccination with 7-valent pneumococcal conjugate vaccine (PCV7) may …

Background Pediatric use of pneumococcal conjugate vaccines (PCV) has been associated
with significant decrease in disease burden. However, disease caused by non-vaccine …